Role of MyD88 signaling in systemic inflammation and Alzheimer disease
MyD88 信号在全身炎症和阿尔茨海默病中的作用
基本信息
- 批准号:10611489
- 负责人:
- 金额:$ 50.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:3xTg-AD mouseAccelerationAgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease patientAlzheimer&aposs disease riskAmyloid beta-ProteinAnimal ModelBacterial InfectionsBindingBone MarrowBrainCASP1 geneCell DeathCellsCentral Nervous SystemChronicCognitionCytoplasmic ProteinDataDementiaDepositionDevelopmentDiseaseDisease ProgressionEarly Onset Familial Alzheimer&aposs DiseaseEtiologyEventFunctional disorderGenetic RiskGenetic studyGoalsIL18 geneImmuneImmune responseIn VitroInflammagingInflammasomeInflammationInflammatoryInnate Immune ResponseInterleukin ActivationInterleukin-1 betaLate Onset Alzheimer DiseaseMYD88 deficiencyMeasuresMediatingMicrogliaMolecularMultiprotein ComplexesNerve DegenerationNeurofibrillary TanglesNeuronsPathogenesisPathogenicityPathologicPathologyPathway interactionsPatientsPeripheralPlayPreventivePreventive measureProductionProteinsRiskRoleSenile PlaquesSignal PathwaySignal TransductionSynapsesSystemTherapeuticVirus Diseasesabeta accumulationbrain parenchymacognitive functioncytokinedementia riskextracellularglial activationhyperphosphorylated tauin vivomarenostrinmild cognitive impairmentmouse modelneuroinflammationneuron lossneuropathologyprotein complexreconstitutionrisk variantsensorsexsystemic inflammatory responsetau Proteinstau aggregationtau-1
项目摘要
Project Summary / Abstract
The main pathological changes found in patients with Alzheimer’s disease (AD) are extracellular amyloid β (Aβ)
deposits in the brain parenchyma (amyloid plaques) and abnormal aggregates of hyperphosphorylated tau
protein in brain neurons (neurofibrillary tangles, NFTs). Amyloid plaques and NFTs are accompanied with chronic
inflammation characterized by activated microglia and increased levels of cytokines. Except a small subset of
early-onset familial AD cases, the causes for the vast majority of AD cases are unknown and satisfactory
therapeutic and preventive measures for AD are unavailable. Therefore, an urgent need exists to identify the
molecular mechanisms that increase the risk for the vast majority of AD cases and to develop the preventive and
therapeutic measures. Systemic inflammation promotes AD progression and even initiates microglial activation
and neurodegeneration. Indeed, recent genetic studies on late-onset AD have identified about a dozen genetic
risk variants that are highly expressed in microglia and involved in innate immune responses, highlighting the
importance of immune responses, particularly activated microglia, in the pathogenesis of late-onset AD. Aging
is the largest known risk factor for AD and is characterized by chronic, systemic inflammation (inflamm-aging).
Systemic inflammation caused by certain bacterial and viral infections is a strong risk factor of dementia, also.
Additionally, our preliminary data indicate that activation of NLRP3 inflammasome through the MyD88 signaling
pathway in microglia in the central nervous system (CNS) plays essential roles in the AD pathogenesis. In Aim
1, we will produce a microglia specific MyD88 deficiency in AD mouse models during aging and determine their
effect on Aβ and tau pathology and cognitive function. We further hypothesize that microglial MyD88 signaling
plays a predominant role in accelerating brain Aβ and tau pathology and neuroinflammation, which are induced
by chronic, systemic inflammation, in AD mouse models during aging. In Aim 2, we will determine the effects of
systemic LPS treatment on Aβ and tau pathology and cognition in AD mouse models with brain and peripheral
immune cell-specific MyD88 deficiency. In Aim 3, we will determine the age and sex dependent effects of LPS
treatment on NLRP3 inflammasome activation as disease mechanisms in the brain/microglia-specific and
peripheral immune cell-specific MyD88 deficient AD mouse models. Our hypothesis is that LPS-induced
systemic inflammation causes NLRP3 inflammasome activation in microglia via MyD88 signaling, leading to
exacerbation of AD-like pathophysiology in AD mouse models. The long term goals are to determine the role of
microglial MyD88/NLRP3 inflammasome signaling in the AD pathogenesis, to elucidate the molecular
mechanism underlying the increased AD risk associated with systemic inflammation and to develop new
preventive and therapeutic strategies for AD.
项目摘要/摘要
阿尔茨海默病(AD)患者的主要病理改变是细胞外淀粉样蛋白β(Aβ)
脑实质中的沉积(淀粉样斑块)和过度磷酸化的tau的异常聚集
脑神经元中的蛋白质(神经原纤维缠结,NFT)。淀粉样斑块和神经营养不良伴发慢性
以小胶质细胞激活和细胞因子水平升高为特征的炎症。除了一小部分
早发性家族性AD病例,绝大多数AD病例病因不明且令人满意
目前尚无治疗和预防阿尔茨海默病的措施。因此,迫切需要确定
分子机制增加了绝大多数AD病例的风险,并开发了预防和
治疗措施。全身炎症促进AD进展,甚至启动小胶质细胞激活
和神经退化。事实上,最近对晚发性阿尔茨海默病的遗传学研究已经确定了大约12个基因
在小胶质细胞中高表达并参与先天性免疫反应的风险变异体,突出了
免疫反应,特别是激活的小胶质细胞,在晚发性AD发病机制中的重要性。老龄化
是已知的AD的最大危险因素,以慢性全身炎症(炎症老化)为特征。
由某些细菌和病毒感染引起的全身炎症也是痴呆症的一个强烈的风险因素。
此外,我们的初步数据表明,NLRP3炎症小体通过MyD88信号被激活
中枢神经系统(CNS)小胶质细胞通路在AD发病机制中起重要作用。在AIM
1,我们将在AD小鼠模型中产生小胶质细胞特异性MyD88缺陷,并确定其
对Aβ和tau病理及认知功能的影响。我们进一步假设小胶质细胞MyD88信号
在加速脑Aβ和tau病理以及神经炎症方面起主导作用
通过慢性、全身性炎症,在AD小鼠模型衰老过程中。在目标2中,我们将确定
系统脂多糖治疗对脑及外周AD模型小鼠A-β和tau病理及认知功能的影响
免疫细胞特异性MyD88缺乏症。在目标3中,我们将确定内毒素的年龄和性别依赖效应
治疗NLRP3炎症体激活作为脑/小胶质细胞特异性和
外周免疫细胞特异性MyD88缺陷AD小鼠模型。我们的假设是,内毒素诱导
全身炎症通过MyD88信号导致小胶质细胞NLRP3炎症体激活,导致
阿尔茨海默病模型小鼠类AD病理生理学的恶化。长期目标是确定
小胶质细胞MyD88/NLRP3炎症信号在AD发病机制中的分子阐明
与全身炎症相关的AD风险增加的潜在机制并开发新的
AD的预防和治疗策略。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A novel co-culture model for investigation of the effects of LPS-induced macrophage-derived cytokines on brain endothelial cells.
- DOI:10.1371/journal.pone.0288497
- 发表时间:2023
- 期刊:
- 影响因子:3.7
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ken-ichiro Fukuchi其他文献
Ken-ichiro Fukuchi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ken-ichiro Fukuchi', 18)}}的其他基金
Role of MyD88 signaling in systemic inflammation and Alzheimer disease
MyD88 信号在全身炎症和阿尔茨海默病中的作用
- 批准号:
10456872 - 财政年份:2021
- 资助金额:
$ 50.13万 - 项目类别:
Role of MyD88 signaling in systemic inflammation and Alzheimer disease
MyD88 信号在全身炎症和阿尔茨海默病中的作用
- 批准号:
10314883 - 财政年份:2021
- 资助金额:
$ 50.13万 - 项目类别:
Altering immune tolerance in Alzheimer disease
改变阿尔茨海默病的免疫耐受性
- 批准号:
9979733 - 财政年份:2019
- 资助金额:
$ 50.13万 - 项目类别:
Role of extracellular vesicles in the high-fat diet-induced risk of Alzheimer disease
细胞外囊泡在高脂肪饮食诱发的阿尔茨海默病风险中的作用
- 批准号:
9385535 - 财政年份:2017
- 资助金额:
$ 50.13万 - 项目类别:
Role of diet-induced miR-34a in Alzheimer disease and dementia
饮食诱导的 miR-34a 在阿尔茨海默病和痴呆中的作用
- 批准号:
9225329 - 财政年份:2017
- 资助金额:
$ 50.13万 - 项目类别:
Role of the MyD88-independent pathway in Alzheimers disease
MyD88 独立通路在阿尔茨海默病中的作用
- 批准号:
8511261 - 财政年份:2013
- 资助金额:
$ 50.13万 - 项目类别:
Role of the MyD88-independent pathway in Alzheimers disease
MyD88 独立通路在阿尔茨海默病中的作用
- 批准号:
8676620 - 财政年份:2013
- 资助金额:
$ 50.13万 - 项目类别:
Catalytic and non-catalytic Ig gene delivery for Alzheimer's disease
阿尔茨海默病的催化和非催化 Ig 基因递送
- 批准号:
7963696 - 财政年份:2010
- 资助金额:
$ 50.13万 - 项目类别:
Catalytic and non-catalytic Ig gene delivery for Alzheimer's disease
阿尔茨海默病的催化和非催化 Ig 基因递送
- 批准号:
8081811 - 财政年份:2010
- 资助金额:
$ 50.13万 - 项目类别:
Innate immunity in Alzheimer's disease: Role of toll-like receptor signaling
阿尔茨海默氏病的先天免疫:Toll 样受体信号传导的作用
- 批准号:
7904117 - 财政年份:2009
- 资助金额:
$ 50.13万 - 项目类别:
相似海外基金
Epigenetic Age Acceleration Impacts Racial and Neighborhood Disparities in Chronic Low Back Pain
表观遗传年龄加速影响慢性腰痛的种族和社区差异
- 批准号:
10431156 - 财政年份:2022
- 资助金额:
$ 50.13万 - 项目类别:
Epigenetic Age Acceleration and Psychoneurological Symptoms in Sickle Cell Disease
镰状细胞病的表观遗传年龄加速和精神神经症状
- 批准号:
10594523 - 财政年份:2022
- 资助金额:
$ 50.13万 - 项目类别:
Early Life Cardiovascular Disease Risk Factors, Epigenetic Age Acceleration, and Alzheimer's Disease Related Brain Health
生命早期心血管疾病危险因素、表观遗传年龄加速和阿尔茨海默病相关的大脑健康
- 批准号:
10706044 - 财政年份:2022
- 资助金额:
$ 50.13万 - 项目类别:
The pathway from prenatal pregnancy-specific anxiety to offspring ADHD through epigenetic age acceleration DNA methylation and moderators to target intervention: Partner social support
通过表观遗传年龄加速 DNA 甲基化和调节因子从产前妊娠特异性焦虑到后代 ADHD 的途径:伴侣社会支持
- 批准号:
475968 - 财政年份:2022
- 资助金额:
$ 50.13万 - 项目类别:
Studentship Programs
Epigenetic Age Acceleration and Psychoneurological Symptoms in Sickle Cell Disease
镰状细胞病的表观遗传年龄加速和精神神经症状
- 批准号:
10449461 - 财政年份:2022
- 资助金额:
$ 50.13万 - 项目类别:
Functional genetic analysis of epigenetic age acceleration and the regulatory landscape of the methylome
表观遗传年龄加速的功能遗传分析和甲基化组的调控景观
- 批准号:
10674263 - 财政年份:2022
- 资助金额:
$ 50.13万 - 项目类别:
Perinatal Maternal Anxiety and Offspring ADHD Symptoms: Mediation Through Epigenetic Age Acceleration DNA Methylation
围产期母亲焦虑和后代 ADHD 症状:通过表观遗传年龄加速 DNA 甲基化进行调节
- 批准号:
467256 - 财政年份:2021
- 资助金额:
$ 50.13万 - 项目类别:
Studentship Programs
CAREER: Understanding the Role of Cu-Containing Secondary Phase Particles in Enhancing the Resistance to the Environmental Acceleration to Fatigue in Age-Hardenable Al Alloys
事业:了解含铜第二相颗粒在增强时效硬化铝合金的环境加速疲劳抵抗力方面的作用
- 批准号:
1943870 - 财政年份:2020
- 资助金额:
$ 50.13万 - 项目类别:
Continuing Grant
Breast Cancer Risk Factors and Epigenetic Age Acceleration
乳腺癌危险因素和表观遗传年龄加速
- 批准号:
10614228 - 财政年份:2020
- 资助金额:
$ 50.13万 - 项目类别:
The Clock is Ticking: Epigenetic Age Acceleration as a Biomarker of Uterine Function in Pregnancy
时钟在滴答作响:表观遗传年龄加速作为妊娠期子宫功能的生物标志物
- 批准号:
10630244 - 财政年份:2020
- 资助金额:
$ 50.13万 - 项目类别:














{{item.name}}会员




